A 35-year-old woman with systemic lupus erythematosus (SLE) presents with mild-to-moderate disease activity involving arthritis and rash. She requires long-term immunosuppression with minimal metabolic side effects. Which corticosteroid is the drug of choice for maintenance therapy in this patient?

Explanation

## Drug of Choice for Chronic SLE Management **Key Point:** Prednisolone is the gold standard corticosteroid for chronic autoimmune diseases requiring long-term maintenance therapy because it offers the optimal balance between anti-inflammatory efficacy and metabolic tolerability. ### Why Prednisolone? **High-Yield:** Prednisolone has: - **Intermediate duration of action** (18–36 hours) — suitable for once-daily dosing - **Moderate potency** — sufficient to control SLE activity without excessive mineralocorticoid effects - **Better safety profile** for prolonged use compared to potent agents - **Established long-term efficacy** in autoimmune conditions with predictable pharmacokinetics ### Comparison of Corticosteroids for Chronic Use | Agent | Potency | Duration | Mineralocorticoid Activity | Best Use | Limitation | |-------|---------|----------|---------------------------|----------|------------| | **Prednisolone** | Intermediate | 18–36 hrs | Minimal | Chronic autoimmune disease | — | | Dexamethasone | Very high | 36–72 hrs | Negligible | Acute CNS/adrenal crisis | Excessive potency for chronic use; suppresses HPA axis more | | Hydrocortisone | Low | 8–12 hrs | High | Physiologic replacement | Requires 3–4 doses daily; high Na^+^ retention | | Betamethasone | Very high | 36–72 hrs | Negligible | Acute severe inflammation | Excessive potency; risk of HPA suppression | **Clinical Pearl:** In SLE, the goal is disease control with the **lowest effective dose** of prednisolone (typically 7.5–15 mg/day) to minimize long-term toxicity (osteoporosis, infections, metabolic syndrome) while maintaining remission. **Warning:** Dexamethasone and betamethasone are reserved for acute, severe flares or life-threatening manifestations (e.g., cerebritis, vasculitis), not maintenance therapy, because their high potency and prolonged action increase cumulative toxicity. ### Maintenance Strategy 1. Initiate prednisolone at moderate dose (0.5–1 mg/kg/day) during active disease 2. Taper gradually as disease control achieved 3. Maintain lowest dose (5–10 mg/day) for remission 4. Combine with steroid-sparing agents (azathioprine, mycophenolate) to allow further dose reduction [cite:KD Tripathi 8e Ch 56]